Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 305

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1A
Chunk 305
---
  
     (9,090,965)

    Cash and cash equivalents restricted cash at beginning of year 
     5,529,484  
     14,620,449 

    Cash and cash equivalents and restricted cash at end of year 
    $5,599,074  
    $5,529,484 

    Supplemental information of non-cash investing and financing activities: 

    Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services 
    $13  
    $35 
  
    Disposal of fully depreciated property 
    $350,670  
    $– 
  
    Reversal of accrued commission liability (see Note 6) 
    $–  
    $404,120 
  
    Deferred offering costs not yet paid 
    $–  
    $219,117 

    Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: 

    Cash and cash equivalents 
    $5,501,261  
    $5,441,978 
  
    Restricted cash 
     97,813  
     87,506 
  
    Cash and restricted cash 
    $5,599,074  
    $5,529,484 

See accompanying notes to the consolidated financial
statements.

 F-8 

Aethlon Medical, Inc. and Subsidiary

Notes to Consolidated Financial Statements

1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION

Aethlon Medical, Inc. (“Aethlon,”
the “Company,” “we” or “us”) is a medical therapeutic company focused on developing the Hemopurifier,
a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and with additional potential
applications e in organ transplantation and other areas of significant unmet needs. In human studies, 164 sessions with 38 patients, the
Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier
has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and
metastasis, and in life-threatening infectious diseases